Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lipopeptide AB
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Diabetic Foot|Inflammation|Melanoma|Leg Ulcer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2300067840 |
ChiCTR2300067840 | N/A |
Recruiting |
COVID-19 |
2026-12-31 |
|||
ChiCTR2200063622 |
ChiCTR2200063622 | N/A |
Recruiting |
Pneumonia|Coronavirus Infections |
2022-09-30 |
|||
NCT06867250 |
NCT06867250 | N/A |
Completed |
Mucositis|Peri-Implantitis |
2021-12-01 |
2025-03-11 |
Primary Endpoints|Treatments |
|
ChiCTR2000029139 |
ChiCTR2000029139 | N/A |
Not yet recruiting |
Unknown |
2021-02-01 |
|||
ChiCTR2000029120 |
ChiCTR2000029120 | N/A |
Not yet recruiting |
Unknown |
2021-02-01 |
|||
NCT04292548 |
Kırıkkale pediatric dentistry | N/A |
Completed |
Oxidative Stress|Tobacco Use Disorder|Dental Caries |
2018-04-15 |
2020-03-12 |
Primary Endpoints|Treatments |
|
NCT03923218 |
NCT03923218 | N/A |
Completed |
Periodontitis |
2012-07-01 |
2025-02-07 |
Primary Endpoints |
|
NCT02225366 |
5P50CA093459-08 | P2 |
Completed |
Melanoma |
2020-11-24 |
2020-12-02 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2018-000536-10 |
HEAL LL-37 | P2 |
Completed |
Leg Ulcer |
2020-07-13 |
2022-03-13 |
Treatments |
|
NCT04098562 |
NCT04098562 | P2 |
Unknown status |
Diabetic Foot|Inflammation |
2019-12-01 |
2021-09-02 |
Primary Endpoints |
|
2012-002100-41 |
2012-002100-41 | P2 |
Completed |
Leg Ulcer |
2013-04-18 |
2022-03-13 |
Treatments |